Tarsus CMO sells 11,578 shares in plan trades
Tarsus Pharmaceuticals’ chief medical officer disclosed pre-planned open-market stock sales totaling 11,578 shares over two days in early September 2026.
Rhea-AI Filing Summary
Tarsus Pharmaceuticals, Inc. (TARS) reported that Chief Medical Officer Elizabeth Yeu Lin sold a total of 11,578 shares of common stock on September 1–2, 2026, at prices between $73.86 and $80.00 per share, including indirect sales through a spouse’s Roth IRA, under Rule 10b5-1 trading plans.
Positive
- None.
Negative
- None.
Insider Trade Summary 10b5-1
Net Seller: 11,578 shares
Net Sell
4 txns
Insider
Lin Elizabeth Yeu
Role
Chief Medical Officer
Sold
11,578 shs ($898K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock F1 | 5,387 | $80.00 | $431K |
| Sale | Common Stock F2 | 1,590 | $80.00 | $127K |
| Sale | Common Stock F1 | 4,601 | $73.86 | $340K |
| holding | Common Stock | -- | -- | -- |
Holdings After Transaction:
Common Stock — 13,320 shares (Direct);
Common Stock — 4,770 shares (Indirect, By Spouse's Roth IRA);
Common Stock — 12,040 shares (Indirect, By 401(k) Plan)
Footnotes (2)
- F1. The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 29, 2026.
- F2. The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 1, 2026.
Key Figures
Total shares sold: 11,578 shares
Sale on September 1, 2026: 4,601 shares at $73.86 per share
Direct sale on September 2, 2026: 5,387 shares at $80.00 per share
+4 more
7 metrics
Total shares sold
11,578 shares
Net shares sold by Chief Medical Officer over September 1–2, 2026
Sale on September 1, 2026
4,601 shares at $73.86 per share
Direct sale of common stock
Direct sale on September 2, 2026
5,387 shares at $80.00 per share
Directly held common stock sold in open-market or private transaction
Indirect sale on September 2, 2026
1,590 shares at $80.00 per share
Common stock held by spouse's Roth IRA sold
Post-transaction Roth IRA holdings
4,770 shares
Indirect ownership by spouse's Roth IRA after September 2, 2026 sale
401(k) Plan holdings
12,040 shares
Indirect ownership by 401(k) Plan as of September 1, 2026
Rule 10b5-1 plan adoption dates
May 29, 2026 and June 1, 2026
Dates the reporting person adopted trading plans governing the sales
Key Terms
Rule 10b5-1 trading plan, Roth IRA, 401(k) Plan, indirect ownership
4 terms
Rule 10b5-1 trading plan regulatory
"The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
Roth IRA financial
"Common Stock held indirectly with nature of ownership "By Spouse's Roth IRA""
A Roth IRA is a retirement savings account you fund with money that’s already been taxed, and withdrawals taken in retirement under the account rules are tax-free. It matters to investors because it shifts the tax bill to today instead of retirement, potentially increasing after-tax income later—think of it like paying for a lifetime subscription now so you can use it without extra charges in the future—helpful for long-term tax planning and flexibility.
401(k) Plan financial
"Common Stock reported as indirectly owned with nature of ownership "By 401(k) Plan""
A 401(k) plan is a workplace retirement account that lets employees set aside part of their pay into a tax-advantaged savings pot, often with employers adding matching contributions — like a workplace piggy bank for future income. It matters to investors because the amount people save and how employers fund these plans influence consumer spending, corporate payroll costs and the flow of money into financial markets, which can affect stock prices and company valuations.
indirect ownership financial
"Indirect ownership indicated where shares are held by spouse's Roth IRA or 401(k) Plan"
FAQ
What insider activity did TARS disclose for Chief Medical Officer Elizabeth Yeu Lin?
Tarsus Pharmaceuticals disclosed that Chief Medical Officer Elizabeth Yeu Lin reported sales of 11,578 shares of common stock on September 1–2, 2026, consisting of both direct holdings and shares held indirectly through a spouse’s Roth IRA.
Were the September 2026 TARS insider sales made under a Rule 10b5-1 plan?
Yes. The filing states the sales were effected by automatic sales pursuant to Rule 10b5-1 trading plans, adopted by the reporting person on May 29, 2026 and June 1, 2026, which pre-arranged the sale instructions.
What indirect TARS holdings does the Form 4 show after the transactions?
After the reported sales, the Form 4 shows 4,770 shares of Tarsus common stock held indirectly through a spouse’s Roth IRA and a separate indirect position of 12,040 shares held through a 401(k) Plan.
AI-generated analysis. How Rhea-AI works. Not financial advice.
